(Total Views: 531)
Posted On: 09/02/2020 5:17:25 PM
Post# of 153986
Good call overall.
I still think NP gives the EFF-DA too much credit. If the EFF-DA was so keen on fast-tracking leronlimab by granting ph2 and ph3 trials, then WTF are they now sputtering to give EUA after a gold-standard, double-blind, accept every applicant without exception, no-one-wants-to-touch m2m group, with statistical significance proving efficacy? Is it that they think its too good to be true?
I still think NP gives the EFF-DA too much credit. If the EFF-DA was so keen on fast-tracking leronlimab by granting ph2 and ph3 trials, then WTF are they now sputtering to give EUA after a gold-standard, double-blind, accept every applicant without exception, no-one-wants-to-touch m2m group, with statistical significance proving efficacy? Is it that they think its too good to be true?
(1)
(0)
